An article in the International Journal of Urology reports new research on treatment options for premature ejaculation (PE). The study focuses on the effectiveness of sildenafil (Viagra), a drug normally used in erectile dysfunction.
This study, which included 180 men, is not only larger, but includes more comprehensive measures of the effectiveness of therapy. Three different treatments were evaluated in this study: sildenafil, paroxetine (another drug used to treat PE), and squeeze therapy. The subjects and their sexual partners monitored changes over 6 months.
Results demonstrated that sildenafil led to higher levels of sexual satisfaction for both the patients and their partners. Sildenafil also lengthened the time between initiation of vaginal penetration and ejaculation.
Overall, sildenafil was the most effective of the three therapies; only mild side effects of short duration were observed in patients using the drug. Additionally, sildenafil has previously been shown to improve erectile function in men also experiencing PE. Thus, while further studies are necessary, sildenafil is a promising agent that may provide better results than current therapies for men suffering from PE with or without ED.
This study was co-authored by LUA urologist Suks Minhas and colleagues from the UK and China. Mr Minhas is one of the few full-time andrologists in the UK and he has published extensively on erectile dysfunction and premature ejaculation.
The abstract for this study is published here.